Celltrion Pharm Gross Profit vs. Cash And Equivalents

068760 Stock  KRW 56,700  600.00  1.07%   
Taking into consideration Celltrion Pharm's profitability measurements, Celltrion Pharm may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Celltrion Pharm's ability to earn profits and add value for shareholders.
For Celltrion Pharm profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Celltrion Pharm to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Celltrion Pharm utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Celltrion Pharm's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Celltrion Pharm over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Celltrion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Celltrion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Celltrion Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Celltrion Pharm Cash And Equivalents vs. Gross Profit Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Celltrion Pharm's current stock value. Our valuation model uses many indicators to compare Celltrion Pharm value to that of its competitors to determine the firm's financial worth.
Celltrion Pharm is number one stock in gross profit category among its peers. It also is number one stock in cash and equivalents category among its peers creating about  1.10  of Cash And Equivalents per Gross Profit. Comparative valuation analysis is a catch-all model that can be used if you cannot value Celltrion Pharm by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Celltrion Pharm's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Celltrion Cash And Equivalents vs. Gross Profit

Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Celltrion Pharm

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
72.93 B
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Celltrion Pharm

Cash

 = 

Bank Deposits

+

Liquidities

 = 
80.19 B
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Celltrion Pharm Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Celltrion Pharm, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Celltrion Pharm will eventually generate negative long term returns. The profitability progress is the general direction of Celltrion Pharm's change in net profit over the period of time. It can combine multiple indicators of Celltrion Pharm, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju, South Korea. Celltrionph is traded on Korean Securities Dealers Automated Quotations in South Korea.

Celltrion Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Celltrion Pharm. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Celltrion Pharm position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Celltrion Pharm's important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Celltrion Pharm without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Volatility Now

   

Portfolio Volatility

Check portfolio volatility and analyze historical return density to properly model market risk
All  Next Launch Module

Use Investing Themes to Complement your Celltrion Pharm position

In addition to having Celltrion Pharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Office Supplies Thematic Idea Now

Office Supplies
Office Supplies Theme
Companies producing and selling office supplies, and accessories. The Office Supplies theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Office Supplies Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Celltrion Stock

To fully project Celltrion Pharm's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Celltrion Pharm at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Celltrion Pharm's income statement, its balance sheet, and the statement of cash flows.
Potential Celltrion Pharm investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Celltrion Pharm investors may work on each financial statement separately, they are all related. The changes in Celltrion Pharm's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Celltrion Pharm's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.